Fig. 2: This figure shows overall survival for the intention to treat (ITT), 1 month, 3 months and 6 months landmark cohorts stratified by depth of haematologic response.

A Kaplan–Meier curve showing the impact of 1-month haematologic response on OS in the ITT cohort. There was no significant difference in survival between CR and VGPR at 1 month—median not reached in both groups (p = 0.753). 87%, 83%, 68% and 63% of patients with a CR at 1 month were alive at the end of 1, 2, 5 and 10 years, respectively. 92%, 87%, 71% and 59% of patients with a VGPR at 1 month were alive at the end of 1, 2, 5 and 10 years, respectively. In contrast, the median OS of patients with PR and NR at 1 month was 61 months (95% CI 43.42–78.57 months, p < 0.005), and 22 months (95% CI 14.54–29.45 months, P < 0.005), respectively. B Kaplan–Meier curve showing the impact of 1-month haematologic response on OS in the 1-month landmark cohort. There was no significant difference in survival between CR and VGPR at 1 month—median not reached in both groups (p = 0.593). 87%, 83%, 68% and 63% of patients with a CR at 1 month were alive at the end of 1, 2, 5 and 10 years (from landmark point), respectively. 92%, 87%, 72% and 58% of patients with a VGPR at 1 month were alive at the end of 1, 2, 5 and 10 years (from landmark point), respectively. In contrast, the median OS of patients with PR and NR at 1 month was 60 months (95% CI 42.42–77.57 months, p < 0.005) and 32 months (95% CI 25.36–38.63 months, P < 0.005), respectively. C Kaplan–Meier curve showing overall survival based on the haematologic response at 3 months in the 3-month landmark cohort. There was no significant difference in survival between CR and VGPR at 3 months—median not reached in both groups (p = 0.230). 93%, 88%, 69% and 55% of patients with a CR at 3 months were alive at the end of 1, 2, 5 and 10 years (from landmark point), respectively. 91%, 84%, 65% and 51% of patients with a VGPR at 3 months were alive at the end of 1, 2, 5 and 9 years (from landmark point), respectively. In contrast, the median OS of patients with PR and NR at 3 months was 47 months (95% CI 27.51–66.48 months, p < 0.005) and 23 months (95% CI 15.93–30.06 months, p < 0.005), respectively. D Kaplan–Meier curve showing overall survival based on the haematologic response at 6 months in the 6-month landmark cohort. There was no significant difference in survival between CR and VGPR at 6 months—median not reached in both groups (p = 0.070). 93%, 88%, 74% and 63% of patients with a CR at 6 months were alive at the end of 1, 2, 5 and 10 years (from landmark point), respectively. 93%, 86%, 61% and 51% of patients with a VGPR at 6 months were alive at the end of 1, 2, 5 and 10 years (from landmark point), respectively. In contrast, the median OS of patients with PR and NR at 6 months was 42 months (95% CI 27.91–56.09 months, p < 0.005) and 22 months (95% CI 16.39–27.60 months, p = 0.006), respectively.